ArticleCureus2026
Evaluating Clinical Outcomes in Children With Acute Osteomyelitis Treated With Intravenous Versus Oral Antimicrobial Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimOsteomyelitis is an infection of the bone that typically requires hospitalization for diagnosis and initial treatment. For many years, it has been assumed that osteomyelitis must be treated with intravenous (IV) antibiotics for the full course of therapy. However, recent data have demonstrated the efficacy of oral (PO) antibiotics. In addition, studies comparing the efficacy of IV versus PO antibiotics in children with osteomyelitis have found that there was no increased incidence of treatment failure when patients were transitioned to PO antibiotics. The Infectious Diseases Society of America 2021 guideline on the management of acute hematogenous osteomyelitis recommends transitioning from IV to PO regimens when an acceptable PO antibiotic is available. This study aimed to evaluate the efficacy and use of IV versus PO antibiotic therapy for the treatment of osteomyelitis at a pediatric tertiary care center.
methodsThis retrospective chart review evaluated patients under 18 years of age admitted from January 2019 to December 2021 with a diagnosis of acute osteomyelitis. Patients were grouped according to the route of antimicrobial administration prescribed at hospital discharge.
resultsFifty-one patients with osteomyelitis were included, with 19 and 32 patients in the PO and IV groups, respectively. There was no difference in the treatment failure rate between the two groups (IV=3 {9.4%} versus PO=2 {10.5%}; p=1.000). Patients in the IV group had higher rates of adverse drug events compared to the PO group (IV=9 {28.1%} versus PO=4 {21.1%}), with diarrhea and drug-induced neutropenia being the most common.
conclusionOral therapy for osteomyelitis may be associated with fewer adverse events than IV therapy, with no difference in treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.